Clinical trials: Coronary Computed Tomographic Angiography
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
- Trial name
- OCEAN(a)-CCTA (NCT07293260)
- Testing
- Olpasiran
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 406 people
- Sponsor
- Amgen
Lipidemia, Coronary Artery Disease
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally…
- Conditions
- Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- Trial name
- REMBRANDT (NCT06305559)
- Testing
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NewAmsterdam Pharma
Coronary Artery Disease
Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography
This is a prospective, multi-center trial conducted at up to 20 US, Canadian, European and Asian centers designed to determine the diagnostic performance of CT-FLOW (the investigational technology) by coronary computed…
- Trial name
- DeFACTO (NCT01233518)
- Testing
- FFR
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- HeartFlow, Inc.
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body VISIPAQUE™ will be…
- Trial name
- NCT00348608
- Testing
- iodixanol
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400)…
- Trial name
- X-ACT (NCT01255722)
- Testing
- iobitridol, iopromide, iomeprol
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 468 people
- Sponsor
- Guerbet
Coronary Artery Disease
Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry
The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.
- Trial name
- CONFIRM2 (NCT04279496)
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- Cleerly, Inc.
Coronary Stenosis, Acute Coronary Syndrome
Coronary Plaque Geometry and Acute Coronary Syndromes
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis
- Trial name
- NCT03702764
- Testing
- CCTA
- Where
- Romania
- Volunteers
- 1,000 people
- Sponsor
- Cardio Med Medical Center
Coronary Artery Disease
Precise Procedural and PCI Plan (P4)
Computed tomography (CT) has become an established tool in the diagnostic workup of patients with suspected coronary artery disease (CAD).
- Trial name
- P4 (NCT05253677)
- Testing
- CT-guided PCI, IVUS-guided PCI
- Where
- 23 sites in United States, Belgium and 6 more
- Volunteers
- 1,090 people
- Sponsor
- CoreAalst BV
Coronary Artery Disease, Hypercholesterolemia
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
The main aim of this trial is to demonstrate that Evolocumab plus routine lipid management is superior to routine lipid management alone in modifying plaque (non-calcified) volume as measured by Artificial Intelligence-enabled…
- Conditions
- Coronary Artery Disease, Hypercholesterolemia, Atheroma, Atherosclerotic Plaque
- Trial name
- NCT07803679
- Testing
- Evolocumab, Routine Lipid Management, Autoinjector
- Volunteers
- 308 people
- Sponsor
- Amgen
Coronary Artery Disease
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's…
- Trial name
- V-PLAQUE (NCT05360446)
- Testing
- Inclisiran sodium 300 mg
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 610 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Computed Tomographic Angiography, Myocardial Infarction (MI)
GSI Cardiac on Revolution Apex - US
The goal of this clinical data collection study is to collect raw CT scan data using a new GSI Cardiac mode on GE HealthCare's Revolution Apex CT system.
- Conditions
- Coronary Computed Tomographic Angiography, Myocardial Infarction (MI), Cardiac Catheterization
- Trial name
- NCT06702917
- Testing
- GSI Cardiac Scan, Standard of Care CCTA, Research CCTA
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Multicentre Registry of CCTA, IVUS and OCT
The Invictus Registry will compare the diagnostic performance of coronary computed tomography angiography (CCTA) versus intravascular imaging by intravenous ultrasound (IVUS) or optical coherence tomography (OCT) for the…
- Trial name
- NCT04066062
- Where
- 9 sites in Japan
- Volunteers
- 1,700 people
- Sponsor
- Cleerly, Inc.
Cardiovascular Diseases
Study of Management Alterations Resulting From CaRi-Heart® Technology in Patients Undergoing Coronary Computed Tomography Angiography (CCTA) for the Evaluation of Coronary Artery Disease: A United States Based Multi-Centre Study (SMART-CCTA-1)
This study is an assessment of the impact of CaRi-Heart® on the clinical management of patients across at least three centres in the USA.
- Trial name
- SMART-CCTA-1 (NCT06986733)
- Volunteers
- 300 people
- Sponsor
- Caristo Diagnostics Limited
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Diagnostic Accuracy Of Seismocardiography for Coronary Artery Disease
This study aims to evaluate a new, non-invasive method for detecting coronary artery disease (CAD) using seismocardiography (SCG) and gyrocardiography (GCG).
- Trial name
- HF-CAD (NCT06880120)
- Testing
- Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing
- Where
- Uzbekistan
- Volunteers
- 1,534 people, healthy volunteers welcome
- Sponsor
- Heart Force Medical Inc.
Coronary Artery Disease
ELUCIDATE FFRct Study
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).
- Trial name
- NCT06018194
- Testing
- ElucidVivo
- Where
- 8 sites in United States
- Volunteers
- 439 people
- Sponsor
- Elucid Bioimaging Inc.